Toxicological Sciences, Vol 49, 5-14, Copyright © 1999 by Society of Toxicology
PL Goering, HV Aposhian, MJ Mass, M Cebrian, BD Beck and MP Waalkes
Inorganic arsenic is considered a high-priority hazard, particularly
because of its potential to be a human carcinogen. In exposed human
populations, arsenic is associated with tumors of the lung, skin, bladder,
and liver. While it is known to be a human carcinogen, carcinogenesis in
laboratory animals by this metalloid has never been convincingly
demonstrated. Therefore, no animal models exist for studying molecular
mechanisms of arsenic carcinogenesis. The apparent human sensitivity,
combined with our incomplete understanding about mechanisms of carcinogenic
action, create important public health concerns and challenges in risk
assessment, which could be met by understanding the role of metabolism in
arsenic toxicity and carcinogenesis. This symposium summary covers three
critical major areas involving arsenic metabolism: its biodiversity, the
role of arsenic metabolism in molecular mechanisms of carcinogenesis, and
the impact of arsenic metabolism on human risk assessment. In mammals,
arsenic is metabolized to mono- and dimethylated species by
methyltransferase enzymes in reactions that require S-adenosyl- methionine
(SAM) as the methyl donating cofactor. A remarkable species diversity in
arsenic methyltransferase activity may account for the wide variability in
sensitivity of humans and animals to arsenic toxicity. Arsenic interferes
with DNA methyltransferases, resulting in inactivation of tumor suppressor
genes through DNA hypermethylation. Other studies suggest that
arsenic-induced malignant transformation is linked to DNA hypomethylation
subsequent to depletion of SAM, which results in aberrant gene activation,
including oncogenes. Urinary profiles of arsenic metabolites may be a
valuable tool for assessing human susceptibility to arsenic carcinogenesis.
While controversial, the idea that unique arsenic metabolic properties may
explain the apparent non-linear threshold response for arsenic
carcinogenesis in humans. In order to address these outstanding issues,
further efforts are required to identify an appropriate animal model to
elucidate carcinogenic mechanisms of action, and to define dose-response
relationships.
ARTICLES
The enigma of arsenic carcinogenesis: role of metabolism
Division of Life Sciences, Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Maryland 20852, USA. plg@cdrh.fda.gov
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D Mishra and S. Flora Differential oxidative stress and DNA damage in rat brain regions and blood following chronic arsenic exposure Toxicology and Industrial Health, May 1, 2008; 24(4): 247 - 256. [Abstract] [PDF] |
||||
![]() |
B. Nemeti and Z. Gregus Glutathione-Dependent Reduction of Arsenate by Glycogen Phosphorylase A Reaction Coupled to Glycogenolysis Toxicol. Sci., November 1, 2007; 100(1): 36 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Lage, A. Nayak, and C. H. Kim Arsenic ecotoxicology and innate immunity Integr. Comp. Biol., December 1, 2006; 46(6): 1040 - 1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kimura, Y. Ishida, T. Hayashi, T. Wada, H. Yokoyama, T. Sugaya, N. Mukaida, and T. Kondo Interferon-{gamma} Plays Protective Roles in Sodium Arsenite-Induced Renal Injury by Up-Regulating Intrarenal Multidrug Resistance-Associated Protein 1 Expression Am. J. Pathol., October 1, 2006; 169(4): 1118 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemeti, I. Csanaky, and Z. Gregus Effect of an Inactivator of Glyceraldehyde-3-Phosphate Dehydrogenase, a Fortuitous Arsenate Reductase, on Disposition of Arsenate in Rats Toxicol. Sci., March 1, 2006; 90(1): 49 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chanda, U. B. Dasgupta, D. GuhaMazumder, M. Gupta, U. Chaudhuri, S. Lahiri, S. Das, N. Ghosh, and D. Chatterjee DNA Hypermethylation of Promoter of Gene p53 and p16 in Arsenic-Exposed People with and without Malignancy Toxicol. Sci., February 1, 2006; 89(2): 431 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Dopp, L. M. Hartmann, U. von Recklinghausen, A. M. Florea, S. Rabieh, U. Zimmermann, B. Shokouhi, S. Yadav, A. V. Hirner, and A. W. Rettenmeier Forced Uptake of Trivalent and Pentavalent Methylated and Inorganic Arsenic and Its Cyto-/genotoxicity in Fibroblasts and Hepatoma Cells Toxicol. Sci., September 1, 2005; 87(1): 46 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemeti and Z. Gregus Reduction of Arsenate to Arsenite by Human Erythrocyte Lysate and Rat Liver Cytosol - Characterization of a Glutathione- and NAD-Dependent Arsenate Reduction Linked to Glycolysis Toxicol. Sci., June 1, 2005; 85(2): 847 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemeti and Z. Gregus Glutathione-Dependent Reduction of Arsenate in Human Erythrocytes--a Process Independent of Purine Nucleoside Phosphorylase Toxicol. Sci., December 1, 2004; 82(2): 419 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Pires Das Neves, F. Carvalho, M. Carvalho, E. Fernandes, E. Soares, M. D. L. Bastos, and M. D. L. Pereira Protective Activity of Hesperidin and Lipoic Acid Against Sodium Arsenite Acute Toxicity in Mice Toxicol Pathol, August 1, 2004; 32(5): 527 - 535. [Abstract] [PDF] |
||||
![]() |
Xing Cui, Song Li, A. Shraim, Y. Kobayashi, T. Hayakawa, S. Kanno, M. Yamamoto, and S. Hirano Subchronic Exposure to Arsenic Through Drinking Water Alters Expression of Cancer-Related Genes in Rat Liver Toxicol Pathol, January 1, 2004; 32(1): 64 - 72. [Abstract] [PDF] |
||||
![]() |
L. Liu, J. R. Trimarchi, P. Navarro, M. A. Blasco, and D. L. Keefe Oxidative Stress Contributes to Arsenic-induced Telomere Attrition, Chromosome Instability, and Apoptosis J. Biol. Chem., August 22, 2003; 278(34): 31998 - 32004. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemeti, I. Csanaky, and Z. Gregus Arsenate Reduction in Human Erythrocytes and Rats--Testing the Role of Purine Nucleoside Phosphorylase Toxicol. Sci., July 1, 2003; 74(1): 22 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Waalkes and J. Liu Purine Nucleoside Phosphorylase: A Fortuitous Cytosolic Arsenate Reductase? Toxicol. Sci., November 1, 2002; 70(1): 1 - 3. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemeti and Z. Gregus Reduction of Arsenate to Arsenite in Hepatic Cytosol Toxicol. Sci., November 1, 2002; 70(1): 4 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wei, H. Wanibuchi, K. Morimura, S. Iwai, K. Yoshida, G. Endo, D. Nakae, and S. Fukushima Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors Carcinogenesis, August 1, 2002; 23(8): 1387 - 1397. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sciandrello, R. Barbaro, F. Caradonna, and G. Barbata Early induction of genetic instability and apoptosis by arsenic in cultured Chinese hamster cells Mutagenesis, March 1, 2002; 17(2): 99 - 103. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, H. Chen, D. S. Miller, J. E. Saavedra, L. K. Keefer, D. R. Johnson, C. D. Klaassen, and M. P. Waalkes Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic Mol. Pharmacol., August 1, 2001; 60(2): 302 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Poirier, C. K. Wise, R. R. Delongchamp, and R. Sinha Blood Determinations of S-Adenosylmethionine, S-Adenosylhomocysteine, and Homocysteine: Correlations with Diet Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 649 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lu, J. Liu, E. L. LeCluyse, Y.-S. Zhou, M.-L. Cheng, and M. P. Waalkes Application of cDNA Microarray to the Study of Arsenic-Induced Liver Diseases in the Population of Guizhou, China Toxicol. Sci., January 1, 2001; 59(1): 185 - 192. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, Y. Liu, R. A. Goyer, W. Achanzar, and M. P. Waalkes Metallothionein-I/II Null Mice Are More Sensitive than Wild-Type Mice to the Hepatotoxic and Nephrotoxic Effects of Chronic Oral or Injected Inorganic Arsenicals Toxicol. Sci., June 1, 2000; 55(2): 460 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huff, P. Chan, and A. Nyska Is the Human Carcinogen Arsenic Carcinogenic to Laboratory Animals? Toxicol. Sci., May 1, 2000; 55(1): 17 - 23. [Full Text] [PDF] |
||||
![]() |
S. Waxman, Y.-k. Jing, Z. Chen, and G.-Q. Chen RESPONSE: Re: Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations J Natl Cancer Inst, October 6, 1999; 91(19): 1691 - 1691. [Full Text] [PDF] |
||||










